Table 1.
Clinicopathological aspects of patients with cutaneous melanoma and clinical features of controls used in screening (stage 1) and validation (stage 2) of single nucleotide variants in human pigmentation-related genes. *The numbers of individuals were not the same included in the study because no consistent information could be obtained from some individuals. NC: values were not computed. P values describe differences between patients and controls and values < 0.05 are presented in bold letters.
| Characteristics | Stage 1 | Stage 2 | ||||
|---|---|---|---|---|---|---|
| Patients n (%) |
Controls n (%) |
p value | Patients n (%) |
Controls n (%) |
p value | |
| Age (years) | ||||||
| ≤ 55 | 55 (53.4) | 93 (90.3) | < 0.0001 | 125 (50.6) | 229 (81.8) | < 0.0001 |
| > 55 | 48 (46.6) | 10 (9.7) | 122 (49.4) | 51 (18.2) | ||
| Gender | ||||||
| Male | 61 (59.2) | 55 (53.4) | 0.48 | 130 (52.6) | 145 (51.8) | 0.84 |
| Female | 42 (40.8) | 48 (46.6) | 117 (47.4) | 135 (48.2) | ||
| Skin color | ||||||
| White | 97 (94.2) | 80 (77.7) | 0.001 | 231 (93.5) | 231 (82.5) | < 0.0001 |
| Non-white | 6 (5.8) | 23 (22.3) | 16 (6.5) | 49 (17.5) | ||
| Phototype* | ||||||
| I or II | 58 (68.2) | 53 (53.0) | 0.05 | 154 (66.7) | 164 (60.1) | 0.12 |
| III to VI | 27 (31.8) | 47 (47.0) | 77 (33.3) | 109 (39.9) | ||
| Sun exposure* | ||||||
| Yes | 70 (82.4) | 52 (52.0) | < 0.0001 | 196 (83.1) | 126 (45.0) | < 0.0001 |
| No | 15 (17.6) | 48 (48.0) | 40 (16.9) | 154 (55.0) | ||
| Type of sun exposure* | ||||||
| None or intermittent | 32 (34.4) | 76 (73.8) | < 0.0001 | 96 (44.2) | 210 (75.0) | < 0.0001 |
| Chronic | 61 (65.6) | 27 (26.2) | 121 (55.8) | 70 (25.0) | ||
| Number of nevi* | ||||||
| ≤ 50 | 68 (80.0) | 91 (97.8) | 0.0001 | 183 (75.9) | 260 (98.1) | < 0.0001 |
| > 50 | 17 (20.0) | 2 (2.2) | 58 (24.1) | 5 (1.9) | ||
| Tumor location | ||||||
| Head | 16 (18.4) | NA | NC | 46 (18.6) | NC | NC |
| Trunk | 41 (47.1) | NA | NC | 118 (47.8) | NC | NC |
| Upper limb | 13 (14.9) | NA | NC | 40 (16.2) | NC | NC |
| Lower limb | 17 (19.6) | NA | NC | 43 (17.4) | NC | NC |
| Histological type* | ||||||
| Superficial spreading | 37 (50.7) | NA | NC | 119 (57.2) | NC | NC |
| Lentigo malign | 9 (12.3) | NA | NC | 26 (12.5) | NC | NC |
| Nodular | 27 (37.0) | NA | NC | 63 (30.3) | NC | NC |
| Breslow thickness (mm)* | ||||||
| ≤ 1.5 | 44 (46.8) | NA | NC | 123 (52.8) | NC | NC |
| > 1.5 | 50 (53.2) | NA | NC | 110 (47.2) | NC | NC |
| Clark level* | ||||||
| I | 14 (16.5) | NA | NC | 31 (13.2) | NC | NC |
| II | 12 (14.1) | NA | NC | 42 (17.9) | NC | NC |
| III | 27 (31.8) | NA | NC | 60 (25.5) | NC | NC |
| IV | 30 (35.3) | NA | NC | 94 (40.0) | NC | NC |
| V | 2 (2.3) | NA | NC | 8 (3.4) | NC | NC |
| TNM stage* | ||||||
| 0 | 12 (13.8) | NA | NC | 30 (12.3) | NC | NC |
| I | 23 (26.4) | NA | NC | 92 (37.7) | NC | NC |
| II | 27 (31.0) | NA | NC | 83 (34.0) | NC | NC |
| III | 22 (25.3) | NA | NC | 27 (11.1) | NC | NC |
| IV | 3 (3.5) | NA | NC | 12 (4.9) | NC | NC |